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Abstract Hereditary diffuse gastric cancer (HDGC) is a
relatively rare disorder, with a mutated CDH1 gene as the
only known cause. Carriers of a germline mutation in
CDH1 have a lifetime risk of [80% of developing diffuse
gastric cancer. As periodic gastric surveillance is of limited
value in detecting early stages of HDGC, prophylactic
gastrectomy is advised for this patient group. Little is
known about other types of familial gastric cancer. The
Dutch working group on hereditary gastric cancer has
formulated guidelines for various aspects of medical
management for families and individuals at high risk of
developing gastric cancer, including criteria for referral,
classification, diagnostics, and periodic gastric surveil-
lance. These guidelines are not limited to HDGC and are
therefore partially complementary to the guidelines on
hereditary diffuse gastric cancer of the international gastric
cancer linkage consortium (IGCLC 2010). In order to
optimize the care and increase the knowledge on hereditary
gastric cancer it is important to centralize medical care for
these patients. National and international collaboration is
warranted to improve the quality of research by increasing
the size of study cohorts.
Keywords Familial gastric cancer  Hereditary diffuse
gastric cancer  CDH1  Gastric surveillance 
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Introduction
Gastric cancer belongs to the most frequent cancer related
death causes worldwide [1], with a 5-year survival of 20%.
The mean age at diagnosis is above age 60. Only 6–7% of
gastric cancers present before age 50 and \2% before age
40. The incidence of gastric cancer varies widely from 4 to
10 per 100.000 in North America, Africa, South Asia and
Oceania to 69 per 100.000 in North-East Asia [2], with
rates in between these in Europe and South America.
Causes of gastric cancer
Environmental and inherited factors
The etiology of gastric cancer is multifactorial, with a role
for both genetic and exogenic factors. The main exogenic
factors are Helicobacter pylori infection, diet and smoking
[3–5]. The strong decrease in incidence in the last decennia
[6] is one of the indications that exogenic factors play an
important role in gastric cancer development.
Gastric cancer is usually sub typed as an intestinal type
and a diffuse type [7]. Mixed types have been reported as
well. Diffuse gastric cancer often contains signet ring cells
and is then indicated as signet ring cell carcinoma (Fig. 1).
Especially the incidence of the distal, intestinal type of
gastric cancer has decreased (Fig. 2). This is partially
caused by the decrease of H. pylori prevalence in the
Western population. The relationship between H. pylori
and the diffuse type of gastric cancer is less clear. For this
type of gastric cancer, no other exogenic risk factors are
known and its incidence has not decreased which suggests
that genetic factors play a more important role in diffuse
gastric cancer [7, 8].
Approximately 5% of gastric cancers is caused by an
autosomal dominant inherited trait, with carriers having a
strongly increased risk of developing gastric cancer and
probably of other types of cancer. Indications for inherited
gastric cancer are: (a) a young age at diagnosis, (b) familial
clustering of gastric cancer, and (c) gastric cancer and the
presence of a second primary cancer in the same patient. In
families with clustering of gastric cancer cases, the diffuse
type is the most frequent, but not the only, presenting
histological type. Familial occurrence of intestinal gastric
cancer is rare, but several cases have been reported [9–11].
Diffuse gastric cancer caused by germline mutations
in the CDH1 gene
Heterozygous inactivating germline mutations in CDH1
are found in about 30% of families fulfilling the diagnostic
criteria for hereditary diffuse gastric cancer (HDGC) as
established by the international gastric cancer linkage
consortium (IGCLC) [12–14]. CDH1 encodes the protein
E-cadherin, which plays an important role in cell–cell
adhesion and the maintenance of epithelial integrity. Loss
of E-cadherin leads to the typical phenotype of diffuse
gastric cancer, which initially spreads within the mucosa
only and at a later stage invades the gastric wall [15, 16].
Fig. 1 a Intramucosal signet ring cell carcinoma, b intra-epithelial
signet ring cells, c invasive signet ring cell carcinoma
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In HDGC caused by germline mutations in CDH1, the
lifetime risk of developing gastric cancer is supposed to be
higher than 80% and the mean age at diagnosis of gastric
cancer is as young as 40 years of age, with a range from
younger than 20 to older than 70. This large variation in
age at diagnosis is seen even within families [17]. Female
carriers have an additional high risk of developing lobular
breast cancer (LBC) with a lifetime risk of 60% by the age
of 80 years, rising from age 40 [12]. Worldwide, about 100
CDH1 mutation positive families have been reported [14].
Because of the high risk of developing gastric cancer and
the limited value of surveillance for high-risk lesions,
prophylactic gastrectomy is advised to mutation carriers in
these families [12, 18]. Despite the small proportion of
gastric cancer patients that originate from HDGC families,
identification of these families is important in order to
initiate preventive measures in these high risk individuals.
Other familial gastric cancer types and hereditary tumour
syndromes
In the majority of families meeting the diagnostic criteria
for HDGC syndrome, no causal gene defect is known. In
most families with intestinal or mixed types of gastric
cancer, or those with unknown subtypes due to lack of
pathological information on those tumors, a genetic cause
cannot be identified as well. In these families, unknown
gastric cancer genes are likely to play a role in gastric
tumorigenesis. In the absence of an identified germline
cancer predisposing mutation prophylactic gastrectomy is
not advised to asymptomatic relatives.
In addition to site-specific familial gastric cancer, an
increased risk of developing gastric cancer is known in
several other hereditary tumour syndromes: hereditary
breast and ovarian cancer (HBOC) [19, 20], Lynch syn-
drome [21], familial adenomatous polyposis (FAP) [22, 23],
MUTYH-associated adenomatous polyposis (MAP) [24],
Peutz-Jeghers syndrome [25], juvenile polyposis syndrome
[26], Li-Fraumeni syndrome [27] and Cowden syndrome
[28]. The incidence of gastric cancer differs between these
syndromes, but is generally low. However, in a subset of
families with these syndromes, a striking clustering of
gastric cancer cases has been observed [19, 21, 27].
Diagnostic work-up and preventive measures: criteria
Referral to genetics services and genetic examination
Because little is known about the different types of inher-
ited gastric cancer and its medical management, we initi-
ated the Dutch national working group on hereditary
gastric cancer in 2006, with several members also partici-
pating in the IGCLC. The main goal of this working group
is to share knowledge, to establish standards of care and to
initiate collaborative studies in order to improve the quality
of medical care of families with hereditary gastric cancer.
Our working group established criteria for the distin-
guishing aspects of care for patients with hereditary or
familial gastric cancer, i.e. referral to genetics services
(Table 1), diagnostic classification of families (Table 2),
medical care for CDH1 mutation carriers (Table 3) and
surveillance (Table 4). This policy was based on the fact
that hereditary gastric cancer is relatively rare and
knowledge on this topic is not widespread among medical
specialists. For this reason, we advised to centralize the
medical care for this patient group in specialized centers
and to collect data for research purposes.
Criteria for referral to genetics services
Criteria for referral are described in Table 1. In most cases,
little or no histological data of malignancies in a family are
known at the time of referral and are therefore not included
in the criteria for referral.
Fig. 2 intestinal type gastric carcinoma
Table 1 Criteria for referral to genetics services
Gastric cancer in one family member before age 40, or
Gastric cancer in 2 first/second degree relatives with one diagnosis
before age 50, or
Gastric cancer in 3 first/second degree relatives independent of
age, or
Gastric cancer and breast cancer in one patient with one diagnosis
before age 50, or
Gastric cancer in one patient and breast cancer in one first/second
degree relative with one diagnosis before age 50
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Clinical diagnosis
After pedigree analysis, verification of diagnoses and, if
possible, review of the histology, the clinical geneticist will
render a clinical diagnosis. This diagnosis is based on
histological subtypes of gastric cancer, the number of
affected family members and the presence of other types of
cancer in a family. Diagnostic criteria are shown in
Table 2.
DNA analysis
DNA analysis may assist in confirming the clinical diag-
nosis. In families with no detected CDH1 mutation and
with presence of breast cancer or colorectal cancer cases,
BRCA1, BRCA2 and/or Lynch syndrome diagnostics can be
considered. In rare cases, specific signs of Cowden syn-
drome, Peutz-Jeghers syndrome or other genetic syn-
dromes, will be the reason for analysis of relevant genes.
If in an affected patient a causal gene mutation is found,
healthy relatives can be tested for that mutation and indi-
vidualized advises can be given based upon their test
results. In families with no affected family members alive,
an attempt can be made to analyze CDH1, BRCA1, BRCA2
or other genes in stored tissue specimens of patients or
otherwise in DNA from healthy, preferably first-degree,
relatives. Lynch syndrome diagnostics preferably starts by
analysis of stored tumour specimens, i.e. studies for pres-
ence of micro-satellite-instability (MSI) and for immuno-
histochemical analysis of the mismatch repair proteins
MLH1, MSH2, MSH6 and PMS2. Even material of
deceased relatives can be investigated for presence of
Lynch syndrome characteristics.
Recommendations for individuals from CDH1 mutation
positive HDGC families
CDH1 mutation carriers are currently advised to undergo
prophylactic total gastrectomy because of their high life-
time risk of developing gastric cancer and the limited value
of surveillance modalities (Table 3).
Counselling
Extensive counseling of mutation carriers is important.
Specific attention must be paid to the preferred age at which
prophylactic gastrectomy will take place, with respect to
education, career, and in females future pregnancies and
Table 2 Diagnostic criteria
1. Hereditary diffuse
gastric cancer (HDGC)
Proven pathogenic CDH1 mutation in
the family
2. Clinical HDGC DGC in 2 first/second degree relatives,
with at least one diagnosis before 50
DGC in 3 or more first/second degree
relatives independent of age
3. Possible HDGC GC in 3 or more first/second degree
relatives, independent of age, with at
least one diffuse type GC
DGC in one patient before age 40
DGC and LBC in one patient




IGC in 2 or more first/second degree
relatives, with at least one diagnosis
before age 50
IGC in 3 or more first/second degree
relatives, independent of age
5. Familial gastric cancer
(FGC)
GC in 2 or more first/second degree
relatives, with at least one diagnosis
before age 50
GC in 3 or more first/second degree
relatives, independent of age
6. Gastric cancer in other
tumour syndromes
GC in 2 or more mutation carriers in
families with:
Lynch syndrome
Hereditary breast and ovarian cancer
(HBOC)






GC gastric cancer, (H)DGC (hereditary) diffuse gastric cancer,
(F)IGC (familial) intestinal gastric cancer, LBC lobular breast cancer
Table 3 Recommendations for members from HDGC families
Prophylactic gastrectomy In CDH1-mutation carriers from age 18 and guided by ages at onset in the family
Gastric surveillance according ‘Cambridge
protocol’
(see Table 4)
In CDH1-mutation carriers from age 20, if prophylactic gastrectomy will not (yet) be
performed
In individuals with 50% chance of carrying a CDH1-mutation
In FDRs of GC patients from clinical HDGC families without a known genetic cause
Breast surveillance
(annual MRI-scan and mammography)
In female carriers of a CDH1-mutation or with 50% chance of carrying a CDH1-mutation,
from age 35
FDRs first-degree relatives, GC gastric cancer, HDGC hereditary diffuse gastric cancer
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related nutritional issues. The ages at gastric cancer diag-
noses in a specific family may be taken into account.
However, the extent to which these ages have a predictive
value in estimating the ages of future cases in this family is
unknown.
Dietary advices
Before a gastrectomy will be carried out, patients will be
referred to a dietitian to optimally prepare them for a
necessary change in dietary pattern after the operation.
This is important to prevent excessive weight loss and
nutritional deficiencies.
Preoperative gastric investigation
The IGCLC guidelines advise preoperative gastric exami-
nation with biopsies of mucosal abnormalities [12]. We
recommend to mention the main goal of this advice, i.e. the
need to complete a gastrectomy by an extensive lymphade-
nectomy in case of preoperatively diagnosed invasive gastric
cancer.
Surgical procedure
The surgical procedure consists of a total gastrectomy with
Roux-en-Y esophagojejunostomy. The distal margin
should be at least 1.0 cm below the pyloric region to ensure
resection through duodenal mucosa. Before performing the
reconstruction, a frozen section procedure of the proximal
margin is warranted to confirm that no gastric cardia
mucosa is left behind and allowing direct re resection. This
measure, which is relatively easy to perform, is recom-
mended here in addition to the IGCLC guidelines [12],
because any residual gastric mucosa may be at risk for
present or subsequent (pre)malignant lesions and inspec-
tion of the z-line may not in all cases be sufficient to
achieve proximal clearance. In our Dutch experience of
prophylactic gastrectomies in 29 CDH1 mutation carriers
[17], we observed that three patients had to undergo
re-intervention because of incomplete removal of proximal
gastric mucosa. Moreover, the presence or absence of
signet ring cells and/or residual gastric mucosa in the
resection margins was not systematically documented. The
majority, but not all of these carriers were operated in
specialized centers by experts in this field. Since we cannot
guarantee that any mutation carrier will be treated in a
high-specialized center and by the most experienced spe-
cialists, we at least aim to provide guidelines in order to
minimize the change of insufficient care and second
interventions.
If no invasive cancer is diagnosed preoperatively, an
extensive lymphadenectomy with higher risk of compli-
cations [29] is considered to be unnecessary as the meta-
static risk of intramucosal carcinomas is exceedingly low.
Pathological investigation
The ‘Swiss roll’ technique is the designated pathological
procedure to find and localize especially presumed pre-
malignant lesions precisely by examining the complete
mucosa [30]. Alternative techniques using extensive sam-
pling are also possible (IGCLG) [12]. The pathology report
should mention all gastric abnormalities and their local-
izations, including infiltrating adenocarcinoma components
and various presumed pre-malignant lesions (intramucosal
and intra-epithelial signet ring cells) as well as the presence
of intestinal metaplasia, intestinal-type dysplasia and the
presence of signs of Helicobacter pylori gastritis. More-
over, histological confirmation of resection margins to
consist of duodenal and esophageal mucosa respectively is
mandatory as well as reporting any abnormalities.
Follow-up
After the operation, long-term follow-up is warranted to
prevent nutritional deficiencies and to detect other late-
presenting effects. In all phases of the process, psychoso-
cial support is an integral part of the medical care of this
patient group. At this moment, little is known about the
psychosocial impact of prophylactic gastrectomies. Data to
assess this impact are currently being collected in a cohort
of Dutch CDH1 mutation carriers.
Because of the rarity of the disease, and also the specific
requirements for surgical and postsurgical care and for
pathological evaluation, we consider it of great importance
to centralize the intensive care for HDGC families in
specialized centers within multidisciplinary medical teams
consisting of a clinical geneticist, gastroenterologist, sur-
geon, pathologist, psychologist and a dietitian.
Table 4 surveillance strategy
HDGC Cambridge-protocol:
Hp-testing and eradication
Annual gastroscopy with ‘high definition’ endoscope
Careful inspection of mucosa during 30 min
Insufflation and desufflation of the stomach
Biopsy of mucosal abnormalities
30 random biopsies (6 from each region: antrum,
angulus/transitional zone, corpus, fundus, cardia)
Other
categories
Gastroduodenoscopy at age 40 (or at an age 5 years
younger than youngest diagnosis in a family)
Hp-testing and eradication
Gastric surveillance only in research setting
Hp helicobacter pylori
Familial gastric cancer 367
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Gastric surveillance
Because of the relative low incidence of gastric cancer,
gastric surveillance is not routinely part of medical care in
Western countries.
In HDGC, the presence of signet ring cells in the gastric
mucosa is considered as a precursor stage of diffuse gastric
carcinoma, although little is known about its natural course
[15, 16]. Longstanding presence of non-proliferative signet
ring cells was shown by our group in 2 CDH1 mutation
carriers from one family [17].
Intestinal gastric carcinomas often are preceded by
H. pylori induced acute gastritis, which subsequently can
progress into chronic gastritis, atrophic gastritis, intestinal
metaplasia and dysplasia and in some cases by an intestinal
type adenoma [31].
Thus, recognizable precursors are present in at least part
of the hereditary gastric cancers. This may lead to an early
diagnosis and may ultimately add to an improved prog-
nosis. For this reason, tracing and follow-up of at-risk
individuals is highly important. In general, it is not known
which premalignant anomalies are to be expected in the
various categories of high risk groups.
The ‘Cambridge surveillance protocol’ (Table 4) is
advised for CDH1 mutation carriers who will not (yet)
undergo a prophylactic gastrectomy, to individuals at 50%
risk of being carrier who are not (yet) willing to be tested for
the mutation as well as for members from HDGC families
without a known CDH1 mutation. Signet ring cells cannot
endoscopically be detected, but may be recognized at histo-
logical examination of random taken biopsies. However, the
risk of sampling error is high. In our series [17], we demon-
strated a wide variability of age at onset and aggressiveness of
DGC and a longstanding presence of dormant signet ring cells
in some patients. The very subtle gastric abnormalities
(superficial vacuolozed cells without the typical morphology
of signet ring cells) [12, 15] in six of 29 prophylactic removed
stomachs were the most consequent, striking and often the
only CDH1-related alterations, but were not recognized at first
pathological examination by experts in this field and only at
revision by a second expert. Moreover, the unknown clinical
relevance of these lesions and the dormant signet ring cells in
some patients emphasizes that the value of gastric surveillance
must be placed in perspective.
In regular medicine, only one gastroscopy with biopsies
is recommended to first-degree relatives of gastric cancer
patients from the other categories of familial gastric cancer
(Table 4), in order to diagnose and treat a possible Heli-
cobacter pylori colonization and to look for macroscopic
mucosal abnormalities that are of clinical relevance. In our
opinion, there is no place for gastric follow-up in regular
medical care, since very little is known about the value,
optimal method and frequency of gastric surveillance.
Gastric surveillance should only be carried out in a
research setting, in centers with expertise in the field of
hereditary gastric cancer.
Conclusions
Hereditary gastric cancer is a rare disease. Besides germline
mutations in the CDH1 gene, few other genetic factors are
known, but in the majority of families no genetic cause can
be identified. A reliable method for the detection of early
stages or precursors of gastric cancer is not yet available. For
these reasons, gastric surveillance in high risk families
should be performed in specialized centers and preferably
within a research setting. The provided criteria for referral to
genetics services, for diagnostic classification, for DNA
analyses and for surveillance may aid in optimizing medical
care for individuals at high risk for developing gastric cancer.
The differentiation between subgroups of familial gastric
cancer, based on histological and family characteristics, will
facilitate research strategies to find yet unknown genetic
factors and to detect early stages and precursors of the dis-
ease. This requires centralization of medical care for this
patient group. Referral of families suspected for hereditary
gastric cancer to family cancer centers is important to
increase the insight into this disease and to inform at-risk
individuals adequately. National and international collabo-
ration in rare diseases as hereditary gastric cancer is war-
ranted to maximize the study cohorts to be investigated.
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Clinical Genetics: M. G. E. M. Ausems (Utrecht), N.
Hoogerbrugge (Nijmegen), I. Kluijt (Amsterdam), R. H.
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Gastroenterologists: A. Cats, E. Dekker, K. Tytgat
(Amsterdam), J. H. Kleibeuker (Groningen), H. F. A.
Vasen (The Netherlands Foundation for Detection of
Hereditary Tumours)
Molecular Genetics: M. Ligtenberg (Nijmegen)
Surgical Oncology: R. van Hillegersberg (Utrecht), J. T.
Plukker (Groningen)
Pathology: N. C. T. van Grieken (Amsterdam), D. de
Jong (Amsterdam), J. H. van Krieken (Nijmegen)
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